Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen
Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) have been reported to be useful markers for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer (SCLC). Recently, pro-gastrin-releasing peptide (Pro-GRP) became available as a sensitive, specif...
Gespeichert in:
| Veröffentlicht in: | Lung cancer (Amsterdam, Netherlands) Netherlands), 2000-03, Vol.27 (3), p.159-167 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 167 |
|---|---|
| container_issue | 3 |
| container_start_page | 159 |
| container_title | Lung cancer (Amsterdam, Netherlands) |
| container_volume | 27 |
| creator | Niho, Seiji Nishiwaki, Yutaka Goto, Koichi Ohmatsu, Hironobu Matsumoto, Taketoshi Hojo, Fumihiko Ohe, Yuichiro Kakinuma, Ryutaro Kodama, Tetsuro |
| description | Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) have been reported to be useful markers for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer (SCLC). Recently, pro-gastrin-releasing peptide (Pro-GRP) became available as a sensitive, specific, and reliable tumor marker for patients with SCLC. The aim of this study is to determine the most useful tumor marker to detect the relapse of SCLC. Furthermore, we analyzed the relationship between tumor markers at relapse and survival from relapse or response to salvage chemotherapy. Medical records were reviewed to obtain serum levels of Pro-GRP, NSE, and CEA before and after the initial chemotherapy, and at relapse. Consecutive 66 patients with SCLC, with an objective response and confirmed relapse treated at the National Cancer Center Hospital East, were analyzed in this study. The percentages of patients whose tumor marker level were elevated before treatment, decreased after the treatment, and increased again at relapse were 67% (95% CI, 55–78) for Pro-GRP, 20% (10–29) for NSE, and 38% (26–50) for CEA. Multivariate analysis indicated that poor performance status before initial treatment and elevated serum levels of lactate dehydrogenase at relapse were poor prognostic factors for patients with recurrent SCLC (
P |
| doi_str_mv | 10.1016/S0169-5002(99)00100-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70960843</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169500299001002</els_id><sourcerecordid>70960843</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-ff43a4e281933d6e6866d4e7a85ab8e37d0fec4dd0fdd276fd576c1430092b2a3</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvhEUA-oAoOATvOOjEXVFVAkSpxKJytWXuyGCV2sJ1FfbS-Hc5mBdy4zFjy94_H_0_Ic87ecMbl29tSVLVlrH6l1GvGOGNV_YBseNfWVSdE_ZBs_iBn5ElKPwrUcqYekzPOpFKyUxtyf-v23vXOgDdIQ08TxnmkUwzVHlKOzlcRB4Tk_J5OOGVnkUKiUBC0zuQQF1VhYErrgBGGgRosZZiL6Dg5vqMmjBNEyO6AFA8wzOUYPP3l8nfqcY7BV2lCs-xC0YcByjjwtuijcT7guIt3wZdL8Nnt0T8lj3oYEj479XPy7eOHr1fX1c2XT5-vLm8qIxTLVd83AhqsO66EsBJlJ6VtsIVuC7sORWtZj6axpVlbt7K321Ya3gjGVL2rQZyTi3Vu8eTnjCnr0aXle-AxzEm3TEnWNaKA2xU0MaQUsddTdCPEO82ZXjLTx8z0EohWSh8z03XRvTg9MO9GtP-o1pAK8PIEQDIw9LE46tJfbllVLNj7FcPixsFh1Mk4LOZbF9FkbYP7zya_AdwkuFw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70960843</pqid></control><display><type>article</type><title>Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Niho, Seiji ; Nishiwaki, Yutaka ; Goto, Koichi ; Ohmatsu, Hironobu ; Matsumoto, Taketoshi ; Hojo, Fumihiko ; Ohe, Yuichiro ; Kakinuma, Ryutaro ; Kodama, Tetsuro</creator><creatorcontrib>Niho, Seiji ; Nishiwaki, Yutaka ; Goto, Koichi ; Ohmatsu, Hironobu ; Matsumoto, Taketoshi ; Hojo, Fumihiko ; Ohe, Yuichiro ; Kakinuma, Ryutaro ; Kodama, Tetsuro</creatorcontrib><description>Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) have been reported to be useful markers for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer (SCLC). Recently, pro-gastrin-releasing peptide (Pro-GRP) became available as a sensitive, specific, and reliable tumor marker for patients with SCLC. The aim of this study is to determine the most useful tumor marker to detect the relapse of SCLC. Furthermore, we analyzed the relationship between tumor markers at relapse and survival from relapse or response to salvage chemotherapy. Medical records were reviewed to obtain serum levels of Pro-GRP, NSE, and CEA before and after the initial chemotherapy, and at relapse. Consecutive 66 patients with SCLC, with an objective response and confirmed relapse treated at the National Cancer Center Hospital East, were analyzed in this study. The percentages of patients whose tumor marker level were elevated before treatment, decreased after the treatment, and increased again at relapse were 67% (95% CI, 55–78) for Pro-GRP, 20% (10–29) for NSE, and 38% (26–50) for CEA. Multivariate analysis indicated that poor performance status before initial treatment and elevated serum levels of lactate dehydrogenase at relapse were poor prognostic factors for patients with recurrent SCLC (
P<0.005). None of the serum levels of Pro-GRP, NSE, and CEA at relapse was a significant prognostic factor and associated with an objective response to salvage chemotherapy. The present study demonstrated that serum levels of Pro-GRP reflect the disease course of patients with SCLC most accurately.</description><identifier>ISSN: 0169-5002</identifier><identifier>EISSN: 1872-8332</identifier><identifier>DOI: 10.1016/S0169-5002(99)00100-2</identifier><identifier>PMID: 10699689</identifier><identifier>CODEN: LUCAE5</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Aged ; Biological and medical sciences ; Biomarkers, Tumor - blood ; Carcinoembryonic Antigen - blood ; Carcinoma, Small Cell - blood ; Carcinoma, Small Cell - diagnosis ; Carcinoma, Small Cell - drug therapy ; CEA ; Female ; Humans ; Lung Neoplasms - blood ; Lung Neoplasms - diagnosis ; Lung Neoplasms - drug therapy ; Male ; Medical Records ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Neoplasm Recurrence, Local - blood ; Neoplasm Recurrence, Local - diagnosis ; Neoplasm Recurrence, Local - drug therapy ; NSE ; Peptide Fragments - blood ; Peptides - blood ; Phosphopyruvate Hydratase - blood ; Pneumology ; Predictive Value of Tests ; Pro-GRP ; Prognostic factor ; Proportional Hazards Models ; Recombinant Proteins - blood ; Relapse ; Retrospective Studies ; Salvage Therapy ; Sensitivity and Specificity ; Small cell lung cancer ; Survival Analysis ; Tumors of the respiratory system and mediastinum</subject><ispartof>Lung cancer (Amsterdam, Netherlands), 2000-03, Vol.27 (3), p.159-167</ispartof><rights>2000 Elsevier Science Ireland Ltd</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-ff43a4e281933d6e6866d4e7a85ab8e37d0fec4dd0fdd276fd576c1430092b2a3</citedby><cites>FETCH-LOGICAL-c390t-ff43a4e281933d6e6866d4e7a85ab8e37d0fec4dd0fdd276fd576c1430092b2a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0169-5002(99)00100-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1300939$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10699689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niho, Seiji</creatorcontrib><creatorcontrib>Nishiwaki, Yutaka</creatorcontrib><creatorcontrib>Goto, Koichi</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Matsumoto, Taketoshi</creatorcontrib><creatorcontrib>Hojo, Fumihiko</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Kakinuma, Ryutaro</creatorcontrib><creatorcontrib>Kodama, Tetsuro</creatorcontrib><title>Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen</title><title>Lung cancer (Amsterdam, Netherlands)</title><addtitle>Lung Cancer</addtitle><description>Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) have been reported to be useful markers for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer (SCLC). Recently, pro-gastrin-releasing peptide (Pro-GRP) became available as a sensitive, specific, and reliable tumor marker for patients with SCLC. The aim of this study is to determine the most useful tumor marker to detect the relapse of SCLC. Furthermore, we analyzed the relationship between tumor markers at relapse and survival from relapse or response to salvage chemotherapy. Medical records were reviewed to obtain serum levels of Pro-GRP, NSE, and CEA before and after the initial chemotherapy, and at relapse. Consecutive 66 patients with SCLC, with an objective response and confirmed relapse treated at the National Cancer Center Hospital East, were analyzed in this study. The percentages of patients whose tumor marker level were elevated before treatment, decreased after the treatment, and increased again at relapse were 67% (95% CI, 55–78) for Pro-GRP, 20% (10–29) for NSE, and 38% (26–50) for CEA. Multivariate analysis indicated that poor performance status before initial treatment and elevated serum levels of lactate dehydrogenase at relapse were poor prognostic factors for patients with recurrent SCLC (
P<0.005). None of the serum levels of Pro-GRP, NSE, and CEA at relapse was a significant prognostic factor and associated with an objective response to salvage chemotherapy. The present study demonstrated that serum levels of Pro-GRP reflect the disease course of patients with SCLC most accurately.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Carcinoma, Small Cell - blood</subject><subject>Carcinoma, Small Cell - diagnosis</subject><subject>Carcinoma, Small Cell - drug therapy</subject><subject>CEA</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Medical Records</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Recurrence, Local - blood</subject><subject>Neoplasm Recurrence, Local - diagnosis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>NSE</subject><subject>Peptide Fragments - blood</subject><subject>Peptides - blood</subject><subject>Phosphopyruvate Hydratase - blood</subject><subject>Pneumology</subject><subject>Predictive Value of Tests</subject><subject>Pro-GRP</subject><subject>Prognostic factor</subject><subject>Proportional Hazards Models</subject><subject>Recombinant Proteins - blood</subject><subject>Relapse</subject><subject>Retrospective Studies</subject><subject>Salvage Therapy</subject><subject>Sensitivity and Specificity</subject><subject>Small cell lung cancer</subject><subject>Survival Analysis</subject><subject>Tumors of the respiratory system and mediastinum</subject><issn>0169-5002</issn><issn>1872-8332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EokvhEUA-oAoOATvOOjEXVFVAkSpxKJytWXuyGCV2sJ1FfbS-Hc5mBdy4zFjy94_H_0_Ic87ecMbl29tSVLVlrH6l1GvGOGNV_YBseNfWVSdE_ZBs_iBn5ElKPwrUcqYekzPOpFKyUxtyf-v23vXOgDdIQ08TxnmkUwzVHlKOzlcRB4Tk_J5OOGVnkUKiUBC0zuQQF1VhYErrgBGGgRosZZiL6Dg5vqMmjBNEyO6AFA8wzOUYPP3l8nfqcY7BV2lCs-xC0YcByjjwtuijcT7guIt3wZdL8Nnt0T8lj3oYEj479XPy7eOHr1fX1c2XT5-vLm8qIxTLVd83AhqsO66EsBJlJ6VtsIVuC7sORWtZj6axpVlbt7K321Ya3gjGVL2rQZyTi3Vu8eTnjCnr0aXle-AxzEm3TEnWNaKA2xU0MaQUsddTdCPEO82ZXjLTx8z0EohWSh8z03XRvTg9MO9GtP-o1pAK8PIEQDIw9LE46tJfbllVLNj7FcPixsFh1Mk4LOZbF9FkbYP7zya_AdwkuFw</recordid><startdate>20000301</startdate><enddate>20000301</enddate><creator>Niho, Seiji</creator><creator>Nishiwaki, Yutaka</creator><creator>Goto, Koichi</creator><creator>Ohmatsu, Hironobu</creator><creator>Matsumoto, Taketoshi</creator><creator>Hojo, Fumihiko</creator><creator>Ohe, Yuichiro</creator><creator>Kakinuma, Ryutaro</creator><creator>Kodama, Tetsuro</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20000301</creationdate><title>Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen</title><author>Niho, Seiji ; Nishiwaki, Yutaka ; Goto, Koichi ; Ohmatsu, Hironobu ; Matsumoto, Taketoshi ; Hojo, Fumihiko ; Ohe, Yuichiro ; Kakinuma, Ryutaro ; Kodama, Tetsuro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-ff43a4e281933d6e6866d4e7a85ab8e37d0fec4dd0fdd276fd576c1430092b2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Carcinoma, Small Cell - blood</topic><topic>Carcinoma, Small Cell - diagnosis</topic><topic>Carcinoma, Small Cell - drug therapy</topic><topic>CEA</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Medical Records</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Recurrence, Local - blood</topic><topic>Neoplasm Recurrence, Local - diagnosis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>NSE</topic><topic>Peptide Fragments - blood</topic><topic>Peptides - blood</topic><topic>Phosphopyruvate Hydratase - blood</topic><topic>Pneumology</topic><topic>Predictive Value of Tests</topic><topic>Pro-GRP</topic><topic>Prognostic factor</topic><topic>Proportional Hazards Models</topic><topic>Recombinant Proteins - blood</topic><topic>Relapse</topic><topic>Retrospective Studies</topic><topic>Salvage Therapy</topic><topic>Sensitivity and Specificity</topic><topic>Small cell lung cancer</topic><topic>Survival Analysis</topic><topic>Tumors of the respiratory system and mediastinum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niho, Seiji</creatorcontrib><creatorcontrib>Nishiwaki, Yutaka</creatorcontrib><creatorcontrib>Goto, Koichi</creatorcontrib><creatorcontrib>Ohmatsu, Hironobu</creatorcontrib><creatorcontrib>Matsumoto, Taketoshi</creatorcontrib><creatorcontrib>Hojo, Fumihiko</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Kakinuma, Ryutaro</creatorcontrib><creatorcontrib>Kodama, Tetsuro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niho, Seiji</au><au>Nishiwaki, Yutaka</au><au>Goto, Koichi</au><au>Ohmatsu, Hironobu</au><au>Matsumoto, Taketoshi</au><au>Hojo, Fumihiko</au><au>Ohe, Yuichiro</au><au>Kakinuma, Ryutaro</au><au>Kodama, Tetsuro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen</atitle><jtitle>Lung cancer (Amsterdam, Netherlands)</jtitle><addtitle>Lung Cancer</addtitle><date>2000-03-01</date><risdate>2000</risdate><volume>27</volume><issue>3</issue><spage>159</spage><epage>167</epage><pages>159-167</pages><issn>0169-5002</issn><eissn>1872-8332</eissn><coden>LUCAE5</coden><abstract>Neuron-specific enolase (NSE) and carcinoembryonic antigen (CEA) have been reported to be useful markers for staging, monitoring treatment, and predicting relapse in patients with small cell lung cancer (SCLC). Recently, pro-gastrin-releasing peptide (Pro-GRP) became available as a sensitive, specific, and reliable tumor marker for patients with SCLC. The aim of this study is to determine the most useful tumor marker to detect the relapse of SCLC. Furthermore, we analyzed the relationship between tumor markers at relapse and survival from relapse or response to salvage chemotherapy. Medical records were reviewed to obtain serum levels of Pro-GRP, NSE, and CEA before and after the initial chemotherapy, and at relapse. Consecutive 66 patients with SCLC, with an objective response and confirmed relapse treated at the National Cancer Center Hospital East, were analyzed in this study. The percentages of patients whose tumor marker level were elevated before treatment, decreased after the treatment, and increased again at relapse were 67% (95% CI, 55–78) for Pro-GRP, 20% (10–29) for NSE, and 38% (26–50) for CEA. Multivariate analysis indicated that poor performance status before initial treatment and elevated serum levels of lactate dehydrogenase at relapse were poor prognostic factors for patients with recurrent SCLC (
P<0.005). None of the serum levels of Pro-GRP, NSE, and CEA at relapse was a significant prognostic factor and associated with an objective response to salvage chemotherapy. The present study demonstrated that serum levels of Pro-GRP reflect the disease course of patients with SCLC most accurately.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>10699689</pmid><doi>10.1016/S0169-5002(99)00100-2</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-5002 |
| ispartof | Lung cancer (Amsterdam, Netherlands), 2000-03, Vol.27 (3), p.159-167 |
| issn | 0169-5002 1872-8332 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70960843 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Biological and medical sciences Biomarkers, Tumor - blood Carcinoembryonic Antigen - blood Carcinoma, Small Cell - blood Carcinoma, Small Cell - diagnosis Carcinoma, Small Cell - drug therapy CEA Female Humans Lung Neoplasms - blood Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Male Medical Records Medical sciences Middle Aged Multivariate Analysis Neoplasm Recurrence, Local - blood Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - drug therapy NSE Peptide Fragments - blood Peptides - blood Phosphopyruvate Hydratase - blood Pneumology Predictive Value of Tests Pro-GRP Prognostic factor Proportional Hazards Models Recombinant Proteins - blood Relapse Retrospective Studies Salvage Therapy Sensitivity and Specificity Small cell lung cancer Survival Analysis Tumors of the respiratory system and mediastinum |
| title | Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Significance%20of%20serum%20pro-gastrin-releasing%20peptide%20as%20a%20predictor%20of%20relapse%20of%20small%20cell%20lung%20cancer:%20comparative%20evaluation%20with%20neuron-specific%20enolase%20and%20carcinoembryonic%20antigen&rft.jtitle=Lung%20cancer%20(Amsterdam,%20Netherlands)&rft.au=Niho,%20Seiji&rft.date=2000-03-01&rft.volume=27&rft.issue=3&rft.spage=159&rft.epage=167&rft.pages=159-167&rft.issn=0169-5002&rft.eissn=1872-8332&rft.coden=LUCAE5&rft_id=info:doi/10.1016/S0169-5002(99)00100-2&rft_dat=%3Cproquest_cross%3E70960843%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70960843&rft_id=info:pmid/10699689&rft_els_id=S0169500299001002&rfr_iscdi=true |